Yumeng Mao
Senior Lecturer/Associate Professor at Department of Immunology, Genetics and Pathology; Research programme: Cancer Immunotherapy; Research group Yumeng Mao
- E-mail:
- yumeng.mao@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
- ORCID:
- 0000-0001-6142-6628
Keywords
- drug discovery
- cancer immune checkpoint
- immune resistance
- crispr-cas9
- pd1
- pdl1
- myeloid cells
Biography
Complete list of publications with citations on google scholar
https://scholar.google.com/citations?user=yx76OvsAAAAJ&hl=en
Research
Yumeng Mao is a Fellow at the Science for Life Laboratory and an associate senior lecturer at the Department of Immunology, Genetics and Pathology in Uppsala University. The research group aims to overcome resistance mechanisms against the PD-1/PD-L1 blockade therapy in cancer patients by elucidating the negative immune regulatory network using CRISPR/Cas9 precise genome editing (PGE) technology. The group has a special interest on rare cancer types where immunotherapy is less explored, e.g. childhood solid cancers. Prior to the appointment, Yumeng spent a few years at the Oncology R&D headquarter at AstraZeneca in Cambridge, United Kingdom, where he identified and led early drug discovery projects for novel cancer immunotherapy targets. He started his research career in cancer immunology in 2009 with Dr. Karl-Erik Hellström at the University of Washington (USA) and trained as a PhD candidate at the Karolinska Institute (Sweden) under the supervision of Prof. Rolf Kiessling. Yumeng was born and raised in Xi’an, China, where he obtained his undergraduate degree in Life Sciences.

Publications
Recent publications
Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma
Part of Journal of Clinical Investigation, 2024
- DOI for Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma
- Download full text (pdf) of Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma
Part of Nature Communications, 2024
- DOI for Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer
- Download full text (pdf) of Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer
Part of Journal of Clinical Investigation, 2023
- DOI for Interleukin-1 receptor-associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy
- Download full text (pdf) of Interleukin-1 receptor-associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy
Part of Frontiers in Immunology, 2021
- DOI for Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy
- Download full text (pdf) of Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy
Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25(+)/CD54(+) NK cells
Part of EMBO Reports, 2021
- DOI for Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25(+)/CD54(+) NK cells
- Download full text (pdf) of Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25(+)/CD54(+) NK cells
All publications
Articles in journal
Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma
Part of Journal of Clinical Investigation, 2024
- DOI for Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma
- Download full text (pdf) of Epigenetic regulation of cell state by H2AFY governs immunogenicity in high-risk neuroblastoma
Part of Nature Communications, 2024
- DOI for Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer
- Download full text (pdf) of Loss of NEDD8 in cancer cells causes vulnerability to immune checkpoint blockade in triple-negative breast cancer
Part of Journal of Clinical Investigation, 2023
- DOI for Interleukin-1 receptor-associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy
- Download full text (pdf) of Interleukin-1 receptor-associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy
Part of Frontiers in Immunology, 2021
- DOI for Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy
- Download full text (pdf) of Editorial: NK-Myeloid Cell Interactions in the Tumor Microenvironment: Implications for Cancer Immunotherapy
Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25(+)/CD54(+) NK cells
Part of EMBO Reports, 2021
- DOI for Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25(+)/CD54(+) NK cells
- Download full text (pdf) of Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25(+)/CD54(+) NK cells
Part of Oncoimmunology, 2021
- DOI for Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients
- Download full text (pdf) of Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients
Part of Current Medicinal Chemistry, p. 5654-5674, 2020
Discovery of PROTAC molecules that selectively degrade the IRAK3 pseudokinase
Part of Journal of Medicinal Chemistry, p. 10460-10473, 2020
Part of Cancer Immunology and Immunotherapy, p. 1391-1401, 2020
- DOI for Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade
- Download full text (pdf) of Human ovarian cancer intrinsic mechanisms regulate lymphocyte activation in response to immune checkpoint blockade
What industry can teach academia
Part of Science, p. 1342-1342, 2019